Legault Pierre's Form 4 filing
Bicycle Therapeutics PLC (BCYC) · filed Dec 22, 2021
- Accession no.
- 0001209191-21-071007
- Filed
- Dec 22, 2021
- Trade date
- Dec 20-22, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $8.65M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Legault PierreCIK 0001391045 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | Ordinary Shares | MOption exerciseAcquired | +7,603 | $8.41F1 | +$63,941.23 | 7,603 | Direct | |
| Dec 20, 2021 | Ordinary Shares | SSaleDisposed | −7,603 | $57.02F3 | −$433,523.06 | 0 | Direct | |
| Dec 21, 2021 | Ordinary Shares | MOption exerciseAcquired | +44,537 | $8.44F4 | +$375,892.28 | 44,537 | Direct | |
| Dec 21, 2021 | Ordinary Shares | SSaleDisposed | −44,537 | $57.11F5 | −$2,543,508.07 | 0 | Direct | |
| Dec 22, 2021 | Ordinary Shares | MOption exerciseAcquired | +97,860 | $8.48F6 | +$829,852.8 | 97,860 | Direct | |
| Dec 22, 2021 | Ordinary Shares | SSaleDisposed | −97,860 | $58.01F7 | −$5,676,858.6 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | Ordinary Shares | MOption exerciseDisposed | −7,603 | $0.00 | $0 | 165,709 | Direct | |
| Dec 21, 2021 | Ordinary Shares | MOption exerciseDisposed | −44,537 | $0.00 | $0 | 121,172 | Direct | |
| Dec 22, 2021 | Ordinary Shares | MOption exerciseDisposed | −97,860 | $0.00 | $0 | 23,312 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.319915 to GBP 1.00 as of December 20, 2021.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5) and (7).
Referenced by the price of 1 transaction in Table I.
- F4
This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.324735 to GBP 1.00 as of December 21, 2021.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.02 to $57.55 inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.331495 to GBP 1.00 as of December 22, 2021.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.51 to $58.50 inclusive.
Referenced by the price of 1 transaction in Table I.